BioLineRx Ltd.
BLRX
$3.27
-$0.07-2.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.20% | -176.85% | 260.87% | 45.26% | -1,302.89% |
| Total Depreciation and Amortization | -32.39% | 6.67% | -90.73% | 111.79% | 76.47% |
| Total Amortization of Deferred Charges | -- | -100.00% | -5.39% | -- | -100.00% |
| Total Other Non-Cash Items | -162.38% | 121.27% | -7.14% | -434.71% | 75.40% |
| Change in Net Operating Assets | -109.47% | 464.52% | -25.12% | 88.06% | 52.33% |
| Cash from Operations | -1,089.83% | 93.17% | 69.91% | 12.37% | 13.28% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -200.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 199.17% | 54.57% | -173.33% | 9.59% | 218.07% |
| Cash from Investing | 199.16% | 54.70% | -173.29% | 9.65% | 217.70% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -0.08% | -0.64% | 89.70% | -1,065.99% | -14.19% |
| Issuance of Common Stock | -88.10% | -73.29% | -2.70% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -157.18% | -83.05% | 952.12% | 8.95% | -105.10% |
| Foreign Exchange rate Adjustments | -82.87% | 626.83% | -150.62% | 100.00% | 129.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.25% | -31.93% | -187.50% | 303.30% | -121.66% |